載體指南
相關服務
載體構建質粒DNA制備
病毒包裝服務
mRNA基因遞送解決方案
CRISPR基因編輯解決方案
shRNA基因敲低解決方案
哺乳動物基因表達慢病毒載體
慢病毒載體系統(tǒng)是一種能非常高效的把外源基因穩(wěn)定整合到哺乳動物細胞中的載體工具。除了常規(guī)質粒轉染外,目前該系統(tǒng)也是把外源基因轉入哺乳動物細胞的最常用方法之一。由于具有目的基因和啟動子選擇的靈活性以及轉染細胞類型的廣泛性兩大特點,使得慢病毒載體系統(tǒng)成為倍受歡迎的外源基因表達系統(tǒng)。
慢病毒載體來源于人類免疫缺陷病毒HIV,屬于逆轉錄病毒家族。野生型慢病毒基因組是線性雙正鏈RNA。
慢病毒重組載體構建完成后與輔助質粒一起轉染進入包裝細胞。在包裝細胞中,位于兩個長末端重復序列(LTR)之間的DNA片段會被轉錄成RNA,由輔助質粒表達的病毒蛋白將其包裝形成病毒顆粒。包裝后的活體病毒將會被釋放到上清液中,可以直接收集或進一步濃縮病毒轉染靶細胞。
當病毒轉導靶細胞時,釋放到宿主細胞中的病毒RNA借助逆轉錄酶逆轉錄成雙鏈DNA,然后隨機整合進宿主細胞的基因組中。在病毒載體中,位于兩個LTR的DNA片段和病毒基因組都會穩(wěn)定整合到靶細胞的基因組中。
通過改造優(yōu)化,我們的慢病毒載體刪除了與病毒包裝和轉導相關的基因(這些基因由輔助質粒進行表達,用于病毒包裝過程),使產生的慢病毒顆粒是復制缺陷型的。即包裝的病毒只具有轉導靶細胞的能力,而無法在靶細胞中進行大量復制,因而具有很高的生物安全性。
關于慢病毒基因表達載體的更多信息,請參考以下文獻。
參考文獻 | 主題 |
---|---|
J Virol. 72:8463 (1998) | The 3rd generation lentivirus vectors |
J Virol. 72:9873 (1998) | Self-inactivating lentivirus vectors |
Science. 272:263 (1996) | Transduction of non-dividing cells by lentivirus vectors |
Curr Gene Ther. 5:387 (2005) | Tropism of lentiviral vectors |
J Virol. 77:4685 (2003) | Impact of cPPT to lentivirus vector transduction |
J Virol. 73:2886 (1999) | WPRE enhances the expression of transgenes |
Nat Protoc. 1:241 (2006) | Production and purification of lentiviral vectors |
亮點
我們目前采用的是第三代慢病毒包裝載體系統(tǒng)。經優(yōu)化,該載體在大腸桿菌體內具有很高的拷貝數,包裝的活病毒具有很高的滴度,對大多數宿主細胞具有高效的轉導能力,能有效地把載體整合到靶細胞基因組并實現外源基因的高水平表達。
外源基因的穩(wěn)定整合:常規(guī)質粒轉染只能實現外源基因的瞬時表達,這種外源基因會隨著宿主細胞的分裂而不斷丟失,在快速分裂的細胞中顯得尤為顯著。相反的是,慢病毒轉導的目的基因能穩(wěn)定地整合到宿主細胞的染色體中 ,因而會隨著宿主細胞的分裂而穩(wěn)定遺傳。
滴度高:我們的病毒載體可以包裝出高滴度的病毒。我們提供的病毒包裝服務,病毒滴度可以達到>109 TU/ml。在這樣的病毒滴度下,如果選擇合適的劑量去轉導體外培養(yǎng)的哺乳動物細胞,則轉導效率可接近100%。
宿主范圍廣泛:我們的病毒包裝系統(tǒng)包裝出來的病毒含有VSV-G包膜蛋白,此蛋白擁有非常廣泛的親和性,可以轉導幾乎所有的哺乳動物細胞,包括分裂細胞,非分裂細胞,原代細胞,穩(wěn)定細胞系,干細胞,分化細胞,貼壁細胞和懸浮細胞等各類哺乳動物細胞,甚至還可以轉導一些非哺乳動物細胞。使用傳統(tǒng)的轉染方式轉導神經元細胞是非常難的,但是采用我們慢病毒載體系統(tǒng)可以輕易的實現神經元細胞的轉導。相對于在某些細胞中具有較低轉導效率的腺病毒和不能用于非分裂細胞的逆轉錄病毒而言,利用我們的慢病毒包裝系統(tǒng)包裝出來的病毒具有廣泛的親和性。
靈活使用啟動子:我們的慢病毒載體已經過優(yōu)化,其5' LTR的啟動子已進行了自失活。因此,客戶可以靈活使用啟動子來驅動目的基因的表達。這相對于只能依賴自身5' LTR啟動子的MMLV載體來說是一個巨大的優(yōu)勢。
基因拷貝數相對均一:通常情況下,采用病毒轉導的方式可以比較均一的將外源基因轉入靶細胞中,而傳統(tǒng)的質粒轉染則呈現出較高的不均一性,導致某些細胞會獲得較多拷貝質粒而某些則會獲得較少甚至完全沒有。
體內外實驗均有效:我們的載體不僅擁有良好的體外細胞轉導能力,同樣適用于體內活體動物實驗。
安全性:我們的病毒載體系統(tǒng)具備了以下兩大特點,因而具有非常高的安全性。一、病毒包裝和轉導所必需的基因由三個輔助質粒分開表達。二、5' LTR的啟動子自失活。因此,在進行病毒包裝和病毒轉導的時候不會產生具有復制能力的病毒顆粒,使用我們的載體對人體的健康威脅也是最低的。
不足之處
載體容量受限:野生型的慢病毒基因組大小約為9.2 kb,而在我們的慢病毒載體中,病毒包裝和轉導的必要元件約為2.8 kb,余下6.4 kb的空間容納客戶的目的序列。當病毒載體超過以上大小限制,病毒的包裝滴度將會大大降低。我們的慢病毒載體除了可以插入靶基因的序列外,還可以插入啟動子和篩選標記等載體元件。如果目的基因和這些載體元件長度超過了6.4 kb,病毒的產量有可能會明顯下降。
技術復雜:使用慢病毒載體時,需要在包裝細胞中產生活病毒,然后測定病毒滴度。因此慢病毒轉染相對于常規(guī)質粒轉染,技術難度更高,周期更長。
載體關鍵元件
CMV promoter: Human cytomegalovirus immediate early promoter. It drives the ubiquitous expression of the downstream marker gene.
5' LTR-ΔU3: A deleted version of the HIV-1 5' long terminal repeat. In wildtype lentivirus, 5' LTR and 3' LTR are essentially identical in sequence. They reside on two ends of the viral genome and point in the same direction. Upon viral integration, the 3' LTR sequence is copied onto the 5' LTR. The LTRs carry both promoter and polyadenylation function, such that in wildtype virus, the 5' LTR acts as a promoter to drive the transcription of the viral genome, while the 3' LTR acts as a polyadenylation signal to terminate the upstream transcript. On our vector, Δ5' LTR is deleted for a region that is required for the LTR's promoter activity normally facilitated by the viral transcription factor Tat. This does not affect the production of viral RNA during packaging because the promoter function is supplemented by the RSV promoter engineered upstream of Δ5' LTR.
Ψ: HIV-1 packaging signal required for the packaging of viral RNA into virus.
RRE: HIV-1 Rev response element. It allows the nuclear export of viral RNA by the viral Rev protein during viral packaging.
cPPT: HIV-1 Central polypurine tract. It creates a "DNA flap" that increases nuclear importation of the viral genome during target cell infection. This improves vector integration into the host genome, resulting in higher transduction efficiency.
Promoter: The promoter driving your gene of interest is placed here.
Kozak: Kozak consensus sequence. It is placed in front of the start codon of the ORF of interest because it is believed to facilitate translation initiation in eukaryotes.
ORF: The open reading frame of your gene of interest is placed here.
WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element. It enhances viral RNA stability in packaging cells, leading to higher titer of packaged virus.
Marker: A drug selection gene (such as neomycin resistance), a visually detectable gene (such as EGFP), or a dual-reporter gene (such as EGFP/Neo). This allows cells transduced with the vector to be selected and/or visualized.
3' LTR-ΔU3: A truncated version of the HIV-1 3' long terminal repeat that deletes the U3 region. This leads to the self-inactivation of the promoter activity of the 5' LTR upon viral vector integration into the host genome (due to the fact that 3' LTR is copied onto 5' LTR during viral integration). The polyadenylation signal contained in ΔU3/3' LTR serves to terminates all upstream transcripts produced both during viral packaging and after viral integration into the host genome.
SV40 early pA: Simian virus 40 early polyadenylation signal. It further facilitates transcriptional termination after the 3' LTR during viral RNA transcription during packaging. This elevates the level of functional viral RNA in packaging cells, thus improving viral titer.
Ampicillin: Ampicillin resistance gene. It allows the plasmid to be maintained by ampicillin selection in E. coli.
pUC ori: pUC origin of replication. Plasmids carrying this origin exist in high copy numbers in E. coli.
VB ID | Vector name | Descriptions |
---|---|---|
VB010000-9492agg | pLV[Exp]-EGFP/Puro-EF1A>mCherry | A 3rd generation mammalian gene expression lentiviral vector encoding EGFP and a puromycin resistance gene (linked by T2A) driven by a CMV promoter as well as mCherry under the control of an EF1A promoter. |
VB900110-2722rff | pLV[Exp]-EGFP/Puro-EF1A>hHBB[NM_000518.5] | A lentiviral gene expression vector encoding EGFP and puromyocin resistance (linked by T2A) under the control of a CMV promoter as well as a human beta-globin gene driven by EF1A. |